

cipaglucosidase alfa-atga (Pombiliti)

Commercial Medical Benefit Drug Policy

Place of Service

Infusion Center Administration

Office Administration

Outpatient Facility Administration

Drug Details

USP Category: GENETIC OR ENZYME OR PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT

Mechanism of Action: Hydrolytic lysosomal glycogen-specific enzyme

HCPCS:

J1203:Injection, cipaglucosidase alfa-atga, 5 mg

How Supplied:

105 mg lyophilized powder in a single-dose vial

Condition(s) listed in policy *(see coverage criteria for details)*

- Late-Onset Pompe Disease (LOPD)

Any condition not listed in this policy requires a review to confirm it is medically necessary. For conditions that have not been approved for intended use by the Food and Drug Administration (i.e., off-label use), the criteria outlined in the Health and Safety Code section 1367.21 must be met.

Special Instructions and Pertinent Information

Provider must submit documentation (such as office chart notes, lab results or other clinical information) to ensure the member has met all medical necessity requirements.

The member's specific benefit may impact drug coverage. Other utilization management processes, and/or legal restrictions may take precedence over the application of this clinical criteria.

Coverage Criteria

The following condition(s) require Prior Authorization/Preservice.

Late-Onset Pompe Disease (LOPD)

Meets medical necessity if all the following are met:

1. Meets ONE of the following:
 - a. Genetic testing showing acid alpha-glucosidase (GAA) mutation
 - b. An enzyme assay showing absent or decreased GAA activity from blood, skin, or muscle tissues
2. Age and weight consistent with FDA-approved indication (adults weighing ≥ 40 kg)
3. Used in combination with Opfolda (miglustat)
4. Inadequate response to one currently approved ERT for LOPD: Lumizyme (alglucosidase alfa) OR Nexviazyme (avalglucosidase alfa-ngpt)

Covered Doses:

Up to 20 mg/kg (of actual body weight) given intravenously every other week

Coverage Period:

Initial: 1 year

Reauthorization: Yearly if there is continued benefit from therapy

ICD-10:

E74.02

References

1. AHFS. Available by subscription at <http://www.lexi.com>
2. DrugDex. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
3. Pombiliti (cipaglucoasidase alfa-atga) Prescribing Information. Amicus Therapeutics US, LLC; Philadelphia, PA: 7/2024.

Review History

Date of Last Annual Review: 1Q2025

Changes from previous policy version:

- No clinical change following annual review.

*Blue Shield of California Medication Policy to Determine Medical Necessity
Reviewed by P&T Committee*